Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 13/20 | 0.88 |
| ▸ | ECE1 | P42892 | 1/20 | 0.85 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.85 |
| ▸ | CCKBR | P32239 | 1/20 | 0.83 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.80 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.77 |
| ▸ | CCKAR | P32238 | 3/20 | 0.76 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366649 | 0.98 | GLP1R (0.88) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29462206 | 0.98 | GLP1R (0.88) | GLP1RECE1MUS81CCKBRNR3C1 | |
| Glp-1 SCHEMBL29353361 | 0.98 | GLP1R (0.89) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL31060658 | 0.98 | GLP1R (0.89) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29358622 | 0.96 | GLP1R (0.82) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL30683162 | 0.95 | GLP1R (0.81) | GLP1RECE1MUS81CCKBRNR3C1 | |
| Oxyntomodulin SCHEMBL29349603 | 0.94 | GLP1R (0.84) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29350003 | 0.94 | GLP1R (0.78) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29540128 | 0.94 | GLP1R (0.79) | GLP1RECE1MUS81CCKBRNR3C1 | |
| SCHEMBL29429436 | 0.94 | GLP1R (0.78) | GLP1RECE1MUS81CCKBRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3547 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144877-A1 | HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODS | MANNKIND CORPORATION (US) | 2026-05-28 | — | — | US | claimed |
| WO-2026099249-A1 | MODIFIED AND UNMODIFIED PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN SUBJECTS HAVING INCREASED AMYLOID-BETA AND/OR PHOSPHO-TAU-PROTEIN LOAD AND/OR NEUROINFLAMMATION | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | claimed |
| WO-2026102153-A1 | POSTBIOTIC AND HERBAL BLEND FOR REGULATING METABOLIC PROCESSES AND PROMOTING WEIGHT LOSS | Resbiotic Nutrition, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260132406-A1 | RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-14 | — | — | US | claimed |
| US-12624080-B2 | Multi-receptor (GLP-1 receptor, GIP receptor, and Gcg receptor) agonist protein | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2026-05-12 | — | — | US | claimed |
| EP-3532092-B1 | IMMUNOGLOBULINS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2026-04-29 | — | — | EP | claimed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | claimed |
| EP-4729635-A2 | DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-12589262-B2 | Neuromodulation techniques | GE Precision Healthcare LLC (US) | 2026-03-31 | — | — | US | claimed |
| US-12584110-B2 | Functional feline pancreatic cells from adipose tissue | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2026-03-24 | — | — | US | claimed |
| EP-3972596-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | Pfizer Inc. (US) | 2022-03-30 | — | — | EP | claimed |
| US-20220093269-A1 | INTEGRATED HEALTH DATA CAPTURE AND ANALYSIS SYSTEM | LABRADOR DIAGNOSTICS LLC (US) | 2022-03-24 | — | — | US | claimed |
| US-11278682-B2 | Device and method for aerosolized delivery of substance to a natural orifice of the body | SIPNOSE LTD. (IL) | 2022-03-22 | — | — | US | claimed |
| WO-2022043171-A1 | ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN HAIR GROWTH REGULATION | MONASTERIUM LABORATORY SKIN & HAIR RESEARCH SOLUTIONS GMBH (DE) | 2022-03-03 | — | — | WO | claimed |
| EP-3960150-A1 | ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN HAIR GROWTH REGULATION | Monasterium Laboratory Skin & Hair Research Solutions GmbH (DE) | 2022-03-02 | — | — | EP | claimed |
| US-20220057395-A1 | BIOMARKERS AND METHODS FOR ASSESSING RESPONSE TO INFLAMMATORY DISEASE THERAPY | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2022-02-24 | — | — | US | claimed |
| US-11254660-B2 | Combinations for treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2022-02-22 | — | — | US | claimed |
| US-20220048868-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | claimed |
| US-11241549-B2 | Dry powder inhaler and system for drug delivery | MANNKIND CORPORATION (US) | 2022-02-08 | — | — | US | claimed |
| US-20220033457-A1 | TREATMENT OF NEUROLOGICAL DISEASES | UNIVERSITY OF LANCASTER (GB) | 2022-02-03 | — | — | US | claimed |